News | April 14, 2010

PET Imaging Agent Identifies Patients with Alzheimers

April 14, 2010 - Researchers found a new amyloid imaging agent for positron emission tomography (PET) to be efficacious in assigning patients with clinically probable Alzheimer's disease (AD) or amnestic mild cognitive impairment (MCI).
The multicenter phase II trial, Primary Outcome Analysis of the Multicentre Phase II Trial of 18F-Flutemetamol, a Pittsburgh Compound B Derivative for In Vivo Beta Amyloid Imaging, focused on 18F-Flutemetamol, a Pittsburgh compound B derivative for in vivo beta amyloid imaging. Primary outcome analysis found the agent used with PET identified patients likely to have AD or amnestic MCI. Results also showed healthy controls (HC) were at a raised versus normal uptake category.
The viability of the agent, 18F-flutemetamol PET, could augment the impact of beta amyloid imaging on research and clinical practice since its use does not require an on-site cyclotron.
In the trial, which GE Healthcare supported, there were 27 patients with early-stage AD, 20 with MCI. Fifteen had HC above and 10 below 55 years. 20 of the AD and 20 of the MCI cases also underwent a 11C-PIB PET. Five central independent readers blinded to the clinical diagnosis assigned the 18F-flutemetamol scans to either raised or normal uptake categories in a binary way on the basis of visual assessment. As a primary outcome, the researchers used clinical diagnosis as SOT to calculate sensitivity and specificity of visual assessment of AD and HC scans. They also determined concordance between visual assignment and assignment based on standardized uptake value ratios in a composite cortical region (SUVRcomp).
They found the visual assessment assigned 25/27 scans from the AD group to the raised category, 1/15 scans from the elderly HC, and 9/20 scans from the MCI group. Sensitivity and specificity with clinical diagnosis as SOT (AD vs HC) was 92.6 percent and 96 percent, respectively. The correlation coefficient between 18F flutemetamol SUVRcomp and 11C-PIB SUVRcomp was 0.94.
The researchers concluded the study met their primary outcome and supports a role for 18F-flutemetamol PET as a potential biomarker for AD-related amyloidosis.
The investigators will present the results from the study on April 16 at the 62nd American Academy of Neurology in Toronto, Canada.
For more information: www.aan.com/go/am10

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Overlay Init